Pharmacology and Pathophysiology of Mutated KCNJ5 Found in Adrenal Aldosterone-Producing Adenomas

Abstract

Somatic mutations of the potassium channel KCNJ5 are found in 40% of aldosterone producing adenomas (APAs). APA-related mutations of KCNJ5 lead to a pathological Na+ permeability and a rise in cytosolic Ca2+, the latter presumably by depolarizing the membrane and activating voltage-gated Ca2+ channels. The aim of this study was to further investigate the effects of mutated KCNJ5 channels on intracellular Na+ and Ca2+ homeostasis in human adrenocortical NCI-H295R cells. Expression of mutant KCNJ5 led to a 2-fold increase in intracellular Na+ and, in parallel, to a substantial rise in intracellular Ca2+. The increase in Ca2+ appeared to be caused by activation of voltage-gated Ca2+ channels and by an impairment of Ca2+ extrusion by Na+/Ca2+ exchangers. The mutated KCNJ5 exhibited a pharmacological profile that differed from the one of wild-type channels. Mutated KCNJ5 was less Ba2+ and tertiapin-Q sensitive but was inhibited by blockers of Na+ and Ca2+-transporting proteins, such as verapamil and amiloride. The clinical use of these drugs might influence aldosterone levels in APA patients with KCNJ5 mutations. This might implicate diagnostic testing of APAs and could offer new therapeutic strategies.